

---

**THE FUNCTION OF NURSING IN CONTEMPORARY HEALTHCARE  
THROUGH PHARMACOGENOMICS AND PERSONALIZED  
MEDICINE**

**Urmila Katru<sup>1</sup>, Hara Gouri Mishra<sup>2</sup>, Pandian B<sup>3</sup>, Perli Raviteja<sup>4</sup>, Syam Sundar Sahoo<sup>5</sup>**

1. Prof. Dr. Urmila Katru, Principal, School of Nursing, Centurion University of Technology and Management, Rayagada.
2. Dr. Hara Gouri Mishra, Associate Professor, School of Pharmacy, Centurion University of Technology and Management, Rayagada.
3. Mr. Pandian B, Associate Professor, College of Nursing, Dr. M.G.R. Educational and Research Institute, Chennai.
4. Mr. Perli Ravi Teja, Assistant Professor, School of Nursing, Centurion University of Technology and Management, Rayagada.
5. Mr. Syam Sundar Sahoo, Assistant Professor, School of Nursing, Centurion University of Technology and Management, Rayagada.

**Corresponding Author: Prof. Dr. Urmila Katru**  
E-mail- [urmi.muni2007@gmail.com](mailto:urmi.muni2007@gmail.com)

---

---

***Article Information:***

***Type of Article:*** Original Article

***Received On:*** 01.12.2025

***Accepted On:*** 11.12.2025

***Published On:*** 19.12.2025

---

---

**ABSTRACT**

Pharmacogenomics and personalized medicine have transformed healthcare by enabling treatment strategies tailored to an individual's genetic profile. As this paradigm shift gains momentum, the role of nurses has become increasingly central due to their proximity to patients and their responsibility in delivering evidence-based, patient-centered care. This paper discusses the function of nursing within the emerging fields of pharmacogenomics and personalized medicine, emphasizing the importance of competency development, patient education, ethical considerations, and interdisciplinary collaboration. Through a narrative review approach, the study highlights how nurses can bridge the gap between genetic science and clinical practice. The findings indicate that nursing professionals are uniquely positioned to advance genomic-

based healthcare through assessment, interpretation, clinical decision-making support, and advocacy. The paper concludes that the integration of pharmacogenomics into nursing practice is essential for optimizing therapeutic outcomes, reducing adverse drug reactions, and improving the overall quality of healthcare delivery.

## INTRODUCTION

The rapid advancement of genomic science has significantly influenced contemporary healthcare. Pharmacogenomics—the study of how genes influence drug responses—forms the foundation of personalized medicine, which aims to customize treatment strategies based on individual variability. These innovations promise reduced adverse drug reactions, enhanced therapeutic efficacy, and improved disease prevention strategies. As frontline healthcare professionals, nurses play a pivotal role in translating genomic knowledge into clinical practice.

Nursing responsibilities have evolved beyond traditional care models. Today's nurses must understand genetic principles, communicate genomic information, participate in clinical decision-making, and advocate for safe and appropriate use of personalized therapies. Despite this growing expectation, many nurses still lack adequate preparation and confidence in genomic literacy. This creates an urgent need to examine the role of nursing within this evolving landscape and establish a clear framework for integrating pharmacogenomics into routine nursing practice.

## METHODS

This paper adopts a **narrative review methodology** to analyze the function of nursing within the context of pharmacogenomics and personalized medicine. A narrative review is appropriate because it allows for thematic synthesis, conceptual discussion, and integration of evidence from diverse sources rather than focusing on a single empirical dataset.

### Data Sources

Published literature from scientific journals, professional nursing organizations, genomic medicine databases, and policy documents were reviewed. Sources included:

- Peer-reviewed articles between 2015–2024
- Guidelines from organizations such as the American Nurses Association (ANA) and National Human Genome Research Institute (NHGRI)
- Reports on genomic competencies in nursing

### Key Search Terms

“Pharmacogenomics,” “Personalized medicine,” “Nursing role,” “Genomic literacy,” “Precision health,” “Ethical issues in genomics,” and “Nurses’ Competencies.”

### **Inclusion Criteria**

- Articles addressing genomic applications in nursing practice
- Studies discussing pharmacogenomics in clinical care
- Publications focusing on patient education or ethical issues in genomics

### **Exclusion Criteria**

- Articles focusing solely on laboratory genetics
- Studies unrelated to clinical nursing practice

### **Data Analysis**

Thematic analysis was conducted to categorize findings into four major areas:

1. Nursing competencies
2. Patient education and advocacy
3. Ethical and legal considerations
4. Interprofessional collaboration

These themes form the foundation of the Results and Discussion sections.

## **RESULTS**

The review identified several critical functions of nursing within the domains of pharmacogenomics and personalized medicine. The findings are organized below according to major thematic categories.

### **1. Development of Pharmacogenomic Competencies**

Nurses are increasingly expected to possess foundational genomic knowledge. The analysis revealed that most nursing roles in precision medicine rely on competencies in:

- Understanding genetic testing and interpretation
- Identifying patients who may benefit from pharmacogenomic testing
- Integrating test results into patient assessments
- Participating in shared decision-making regarding treatment adjustments

Studies show that nurses with higher genomic literacy significantly improve medication safety and treatment outcomes.

## **2. Patient Education and Counseling**

A major theme identified is the nurse's role in educating patients about:

- The purpose and benefits of pharmacogenomic testing
- Interpretation of results in simple language
- Possible limitations or uncertainties in genomic data
- How genetic factors influence drug metabolism and response

Nurses act as primary communicators who promote health literacy and help patients make informed decisions about their care.

## **3. Ethical, Legal, and Social Considerations**

The review highlights significant ethical and professional responsibilities associated with genomic practice:

- Maintaining patient confidentiality
- Respecting autonomy in genetic decision-making
- Addressing concerns about genetic discrimination
- Ensuring informed consent for genetic testing

Nurses are ethically obligated to support patient rights while managing sensitive information responsibly.

## **4. Interprofessional Collaboration**

Nurses serve as vital liaisons between patients and healthcare teams. Their role includes:

- Collaborating with genetic counselors, pharmacists, and physicians
- Communicating genomic findings
- Coordinating individualized care plans
- Monitoring drug responses over time

This collaborative approach strengthens accuracy in medication management and enhances continuity of care.

## **DISCUSSION**



The integration of pharmacogenomics into nursing practice represents one of the most significant shifts in modern healthcare delivery. As precision medicine expands, nurses must transition from passive participants to active contributors in genomic-based care. The thematic findings underline that nurses are essential catalysts in applying pharmacogenomic data to real-world practice, but gaps in competency remain a major challenge.

### **Implications for Nursing Education**

Current curricula often lack sufficient genomic content. To practice effectively, nurses require:

- Enhanced genomic training
- Hands-on exposure to real clinical cases
- Continuous education and certification in precision health

Improving education will help nurses interpret complex genetic results and confidently communicate them to patients.

### **Implications for Clinical Practice**

Nurses are positioned to:

- Identify patients at risk for adverse drug reactions
- Monitor treatment effectiveness
- Advocate for pharmacogenomic testing when appropriate
- Integrate genetic factors into holistic assessments

These responsibilities elevate nursing practice and contribute to safer, more effective patient outcomes.

### **Ethical and Policy Considerations**

As genomic testing becomes more widespread, nurses must ensure patients are protected from potential misuse of genetic information. Nursing leaders must advocate for:

- Standardized policies
- Clear consent procedures
- Protection against genetic discrimination

### **Future Directions**

The future of nursing lies in a fully integrated genomic practice framework. Efforts must focus

on:

- Building national competency standards
- Encouraging interprofessional genomic teams
- Increasing genomic research led by nurses
- Expanding access to personalized medicine services

By embracing these transformations, nurses can strengthen their role in shaping the future of healthcare.

## CONCLUSION

Pharmacogenomics and personalized medicine offer transformative opportunities to improve healthcare outcomes. Nurses, as frontline practitioners, hold a critical role in integrating genomic innovations into clinical practice. The review highlights that nursing responsibilities now encompass education, ethical decision-making, clinical interpretation of genomic information, and collaboration within multidisciplinary teams. Strengthening genomic competencies and addressing ethical considerations will empower nurses to provide safer, more effective, and individualized patient care.

## REFERENCES

1. Abdelhalim, H., Berber, A., Lodi, M., Jain, R., Nair, A. S., Pappu, A., Patel, K., Venkat, V., Venkatesan, C., Wable, R., Dinatale, M., Fu, A., Iyer, V., Kalove, I., Kleyman, M., Koutsoutis, J., Menna, D., Paliwal, M., Patel, N., ... Ahmed, Z. (2022). Artificial intelligence, healthcare, clinical genomics, and pharmacogenomics approaches in precision medicine. *Frontiers in Genetics, 13*.  
<https://doi.org/10.3389/fgene.2022.929736>
2. Abrahams, E., & Silver, M. (2009). The case for personalized medicine. *Journal of Diabetes Science and Technology, 3*(4), 680.  
<https://doi.org/10.1177/193229680900300411>
3. Ajani, K., & Moez, S. (2011). Gap between knowledge and practice in nursing. *Procedia – Social and Behavioral Sciences, 15*, 3927–3931.  
<https://doi.org/10.1016/j.sbspro.2011.04.396>
4. Al-Ghoul, M., & Valdes, R. (2008). Fundamentals of pharmacology and applications in pharmacogenetics. *Clinics in Laboratory Medicine, 28*(4), 485–497.  
<https://doi.org/10.1016/j.cll.2008.07.001>
5. Álvarez, M. P., Marcos-Vadillo, E., García-Berrocal, B., & Isidoro-García, M. (2018). Farmacogenómica: La medicina personalizada. *Revista del Laboratorio Clínico, 12*(3), 147–155. <https://doi.org/10.1016/j.labcli.2018.07.004>
6. Bennett, C. C., Doub, T. W., & Selove, R. (2012). EHRs connect research and practice: Where predictive modeling, artificial intelligence, and clinical decision support

- intersect. *Health Policy and Technology*, 1(2), 105–114.  
<https://doi.org/10.1016/j.hlpt.2012.03.001>
7. Borad, M. J., Egan, J. B., Condjella, R., Liang, W. S., Fonseca, R., Ritacca, N. R., McCullough, A. E., Barrett, M. T., Hunt, K. S., Champion, M. D., Patel, M. D., Young, S. W., Silva, A. C., Ho, T. H., Hálfðánarson, Þ. R., McWilliams, R. R., Lazaridis, K. N., Ramanathan, R. K., Baker, A., ... Bryce, A. H. (2016). Clinical implementation of integrated genomic profiling in patients with advanced cancers. *Scientific Reports*, 6(1).  
<https://doi.org/10.1038/s41598-016-0021-4>
  8. Brazell, C., Freeman, A., & Mosteller, M. (2002). Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance. *British Journal of Clinical Pharmacology*, 53(3), 224–231. <https://doi.org/10.1046/j.0306-5251.2001.01556.x>
  9. Brouse, S. D., Fullerton, J. C., & Moridani, M. (2010). Reporting and interpretation of the CYP2C19 genotyping test for clopidogrel dosing. *Current Pharmacogenomics and Personalized Medicine*, 8(4), 268–274. <https://doi.org/10.2174/187569210793368168>
  10. Brown, N. A., & Elenitoba-Johnson, K. S. J. (2020). Enabling precision oncology through precision diagnostics. *Annual Review of Pathology: Mechanisms of Disease*, 15, 97–121. <https://doi.org/10.1146/annurev-pathmechdis-012418-012735>
  11. Bryant, E., Marks, P., Griffiths, K. R., Boulet, S., Pehlivan, M., Barakat, S., Touyz, S., & Maguire, S. (2025). Treating the individual: Moving towards personalised eating disorder care. *Journal of Eating Disorders*, 13(1). <https://doi.org/10.1186/s40337-025-01246-6>
  12. Cacabelos, R., Torrellas, C., & Carrera, I. (2015). Opportunities in pharmacogenomics for the treatment of Alzheimer's disease. *Future Neurology*, 10(3), 229–252.  
<https://doi.org/10.2217/fnl.15.12>
  13. Calzone, K. A., Cashion, A. K., Feetham, S., Jenkins, J., Prows, C. A., Williams, J. K., & Wung, S. (2010). Nurses transforming health care using genetics and genomics. *Nursing Outlook*, 58(1), 26–35. <https://doi.org/10.1016/j.outlook.2009.05.001>
  14. Cavallari, L. H., & Limdi, N. A. (2009). Warfarin pharmacogenomics. *Pharmacotherapy*, 11(3), 243–256. <https://pubmed.ncbi.nlm.nih.gov/19479657>
  15. Cecchin, E., & Stocco, G. (2020). Pharmacogenomics and personalized medicine. *Genes*, 11(6), 679. <https://doi.org/10.3390/genes11060679>
  16. Chaudhary, R., Singh, B., Kumar, M., Gakhar, S. K., Saini, A. K., Parmar, V. S., & Chhillar, A. K. (2015). Role of SNPs in pharmacogenomics and their association with human diseases. *Drug Metabolism Reviews*, 47(3), 281–298.  
<https://doi.org/10.3109/03602532.2015.1047027>
  17. Daack-Hirsch, S., Jackson, B., Belchez, C. A., Elder, B. L., Hurley, R., Kerr, P., & Nissen, M. K. (2013). Integrating genetics and genomics into nursing curricula. *Nursing Clinics of North America*, 48(4), 661–674. <https://doi.org/10.1016/j.cnur.2013.08.005>
  18. Dash, R., Sahu, A., Panda, M. K., Das, M., & Singh, Y. D. (2021). Genomics in clinical care through precision medicine and personalized treatments. In *Elsevier eBooks* (p. 49). <https://doi.org/10.1016/b978-0-323-89824-9.00004-5>
  19. Dilles, T., Heczková, J., Tziaferi, S., Helgesen, A. K., Grøndahl, V. A., Rompaey, B. V., Sino, C., & Jordan, S. (2021). Nurses and pharmaceutical care: Interprofessional, evidence-based working to improve patient care and outcomes. *International Journal of*

- Environmental Research and Public Health*, 18(11), 5973.  
<https://doi.org/10.3390/ijerph18115973>
20. Dreisbach, C., & Koleck, T. A. (2020). The state of data science in genomic nursing. *Biological Research for Nursing*, 22(3), 309–318.  
<https://doi.org/10.1177/1099800420915991>
21. Erickson, R. P. (1998). From “magic bullet” to “specially engineered shotgun loads”: The new genetics and individualized pharmacotherapy. *BioEssays*, 20(8), 683–690.  
[https://doi.org/10.1002/\(SICI\)1521-1878\(199808\)20:8<683::AID-BIES12>3.0.CO;2-V](https://doi.org/10.1002/(SICI)1521-1878(199808)20:8<683::AID-BIES12>3.0.CO;2-V)
22. Evers, A. W. M., Rovers, M. M., Kremer, J. A. M., Veltman, J. A., Schalken, J. A., Bloem, B. R., & van Gool, A. J. (2012). An integrated framework of personalized medicine: From individual genomes to participatory health care. *Croatian Medical Journal*, 53(4), 301–307. <https://doi.org/10.3325/cmj.2012.53.301>
23. (Author missing). *Methods in Molecular Biology*, 143. [https://doi.org/10.1007/978-1-4939-3136-1\\_11](https://doi.org/10.1007/978-1-4939-3136-1_11)
24. Fr, V., C, I. B., & Pursel, M. (2010). Personalized medicine: Part 1—Evolution and development into theranostics. *PubMed*. <https://pubmed.ncbi.nlm.nih.gov/21037908>
25. Gameiro, G. R., Sinkunas, V., Liguori, G. R., & Júnior, J. O. C. A. (2018). Precision medicine: Changing the way we think about healthcare. *Clinics*, 73, e723.  
<https://doi.org/10.6061/clinics/2017/e723>
26. Ghoreyshi, N., Heidari, R., Farhadi, A., Chamanara, M., Farahani, N. J., Vahidi, M., & Behroozi, J. (2025). Next-generation sequencing in cancer diagnosis and treatment: Clinical applications and future directions. *Discover Oncology*, 16(1).  
<https://doi.org/10.1007/s12672-025-01816-9>
27. Goldstein, D. B., Need, A. C., Singh, R., & Sisodiya, S. M. (2007). Potential genetic causes of heterogeneity of treatment effects. *The American Journal of Medicine*, 120(4).  
<https://doi.org/10.1016/j.amjmed.2007.02.004>
28. Green, E. D., et al. (2020). Strategic vision for improving human health at the forefront of genomics. *Nature*, 586(7831), 683–692. <https://doi.org/10.1038/s41586-020-2817-4>
29. Hamilton, R. (2009). Nursing advocacy in a postgenomic age. *Nursing Clinics of North America*, 44(4), 435–446. <https://doi.org/10.1016/j.cnur.2009.07.007>
30. Brothers, K. B., Malin, B., Koenig, B. A., Sanderson, S. C., Rothstein, M. A., Williams, M. S., Clayton, E. W., & Kullo, I. J. (2013). Ethical, legal, and social implications of incorporating genomic information into electronic health records. *Genetics in Medicine*, 15(10), 810–816. <https://doi.org/10.1038/gim.2013.117>
31. Issa, A. M. (2020). Personalized medicine and the practice of medicine in the 21st century. *McGill Journal of Medicine*, 10(1). <https://doi.org/10.26443/mjm.v10i1.625>
32. Johnson, S. G., Shaw, P. B., Delate, T., Kurz, D., Gregg, D., Darnell, J. C., & Aquilante, C. L. (2017). Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization. *Pharmacy Practice*, 15(2), 946.  
<https://doi.org/10.18549/pharmpract.2017.02.946>
33. Kalow, W. (1980). Pharmacogenetics of drug metabolism. *Trends in Pharmacological Sciences*, 1(2), 403–407. [https://doi.org/10.1016/0165-6147\(80\)90063-2](https://doi.org/10.1016/0165-6147(80)90063-2)
34. Kassam, S., Meyer, P., Corfield, A. P., Mikuz, G., & Sergi, C. (2005). Single nucleotide polymorphisms: History, biotechnological outlook and practical applications. *Current Pharmacogenomics*, 3(3), 237–245. <https://doi.org/10.2174/1570160054864021>

35. Kessler, C. (2018). Genomics and precision medicine: Implications for critical care. *AACN Advanced Critical Care*, 29(1), 28–37. <https://doi.org/10.4037/aacnacc2018521>
36. Kim, B., Yoon, D. Y., Lee, S., Jang, I., Yu, K., Cho, J., & Oh, J. (2021). Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform. *Translational and Clinical Pharmacology*, 29(3), 135. <https://doi.org/10.12793/tcp.2021.29.e14>
37. Kowal, S., & Clark, D. (2019). Communicating genomic risk in primary health care: Challenges and opportunities. *Health Science Inquiry*, 5(1). <https://doi.org/10.29173/hsi146>
38. Laing, R. E., Hess, P., Shen, Y., Wang, J., & Hu, S. X. (2011). The role and impact of SNPs in pharmacogenomics and personalized medicine. *Current Drug Metabolism*, 12(5), 460–473. <https://doi.org/10.2174/138920011795495268>
39. Lally, J., Gaughran, F., Timms, P., & Curran, S. (2016). Treatment-resistant schizophrenia: Pharmacogenomics of antipsychotics. *Pharmacogenomics and Personalized Medicine*, 117. <https://doi.org/10.2147/PGPM.S115741>
40. Latapiat, V., Sáez, M. A., Pedroso, I., & Martín, A. J. M. (2023). Unraveling patient heterogeneity through individualized co-expression networks. *Frontiers in Genetics*, 14. <https://doi.org/10.3389/fgene.2023.1209416>
41. Liao, W., & Tsai, F. (2013). Personalized medicine: A paradigm shift in healthcare. *Biomedicine*, 3(2), 66–72. <https://doi.org/10.1016/j.biomed.2012.12.005>
42. Luczak, T., Stenehjem, D. D., & Brown, J. T. (2021). Applying an equity lens to pharmacogenetic research. *Clinical and Translational Science*, 14(6), 2117–2128. <https://doi.org/10.1111/cts.13110>
43. Lysaght, T., Lim, H. Y., Xafis, V., & Ngiam, K. Y. (2019). AI-assisted decision-making in healthcare. *Asian Bioethics Review*, 11(3), 299–314. <https://doi.org/10.1007/s41649-019-00096-0>
44. Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Innovative in silico approaches in precision medicine. *Pharmaceutics*, 16(3), 332. <https://doi.org/10.3390/pharmaceutics16030332>
45. Mathur, S., & Sutton, J. (2017). Personalized medicine could transform healthcare. *Biomedical Reports*, 7(1), 3–5. <https://doi.org/10.3892/br.2017.922>
46. McKinnon, R. A., & Ward, M. (2003). The emergence of pharmacogenomics. *Journal of Pharmacy Practice and Research*, 33(2), 133–137. <https://doi.org/10.1002/jppr2003332133>
47. Lindor, N. M., et al. (2013). Cancer pharmacogenomics: Early promise but effort needed. *Science*, 339(6127), 1563–1564. <https://doi.org/10.1126/science.1234139>
48. Bryant, C. (2010). Technological advances in genetic testing. *Journal of Pediatric Nursing*, 25(5), 444–451. <https://doi.org/10.1016/j.pedn.2010.06.007>
49. Nair, S. (2010). Personalized medicine: Striding from genes to medicines. *Perspectives in Clinical Research*, 1(4), 146–150. <https://doi.org/10.4103/2229-3485.71775>
50. Naithani, N., Sinha, S., Misra, P., Vasudevan, B., & Sahu, R. (2021). Precision medicine: Concepts and tools. *Medical Journal Armed Forces India*, 77(3), 249–255. <https://doi.org/10.1016/j.mjafi.2021.06.021>

51. National Academies of Sciences, Engineering, and Medicine. (2019). *Next-generation diagnostic tests: Exploring the benefits, challenges, and regulatory landscape*. National Academies Press. <https://doi.org/10.17226/25338>
52. Need, A. C., Motulsky, A. G., & Goldstein, D. B. (2005). Priorities and standards in pharmacogenetic research. *Nature Genetics*, 37(7), 671–681. <https://doi.org/10.1038/ng1587>
53. Nicolas, P., Veyrat-Follet, C., & Comets, E. (2009). Genetic polymorphisms and variability in drug response: An overview. *Therapie*, 64(5), 365–370. <https://doi.org/10.2515/therapie/2009064>
54. O'Donnell, P. H., Danahey, K., Jacobs, M., & Wehbe, F. H. (2016). Adoption of a clinical pharmacogenomics testing program during outpatient care. *Clinical Pharmacology & Therapeutics*, 99(3), 415–421. <https://doi.org/10.1002/cpt.285>
55. O'Grady, E. T. (2019). The role of nurses in precision and genomic healthcare. *Nursing Management*, 50(5), 20–27. <https://doi.org/10.1097/01.NUMA.0000554340.28429.45>
56. Ohashi, M., Sasagawa, Y., & Inoue, M. (2020). Artificial intelligence in healthcare: Past, present, and future. *Japan Journal of Nursing Science*, 17(3). <https://doi.org/10.1111/jjns.12365>
57. Palmi, C., & Bailey, D. G. (2020). Drug–gene interactions: A key component of personalized medicine. *Clinical Pharmacokinetics*, 59(9), 1125–1138. <https://doi.org/10.1007/s40262-020-00890-5>
58. Parasuraman, S., Raveendran, R., & Kesavan, R. (2014). Blood sample collection and storage: Methods in pharmacogenomics. *Journal of Pharmacology & Pharmacotherapeutics*, 5(3), 231–234. <https://doi.org/10.4103/0976-500X.136119>
59. Paynter, N. P., & Million Veteran Program. (2016). The emerging science of precision medicine. *The American Journal of Epidemiology*, 183(4), 277–285. <https://doi.org/10.1093/aje/kwv322>
60. Petersen, B. S., & Fredrich, B. (2020). Opportunities and challenges of whole genome sequencing for precision medicine. *Human Genetics*, 139(1), 1–12. <https://doi.org/10.1007/s00439-019-02002-6>
61. Phillips, K. A., Deverka, P. A., Hooker, G. W., & Douglas, M. P. (2015). Genetic test availability and coverage in the U.S. *Health Affairs*, 34(10), 1762–1769. <https://doi.org/10.1377/hlthaff.2015.0635>
62. Plöthner, M., Rübenach, S., & Frank, M. (2020). Value of healthcare interventions in personalized medicine. *The Patient – Patient-Centered Outcomes Research*, 13(6), 667–677. <https://doi.org/10.1007/s40271-020-00449-4>
63. Rathore, A. S., & Wani, S. A. (2020). SNPs and pharmacogenomics: A pathway to individualized therapy. *Journal of Molecular Diagnostics*, 22(1), 1–15. <https://doi.org/10.1016/j.jmoldx.2019.08.005>
64. Relling, M. V., & Klein, T. E. (2011). CPIC guidelines for gene–drug interactions. *Clinical Pharmacology & Therapeutics*, 89(3), 464–467. <https://doi.org/10.1038/clpt.2010.279>
65. Richardson, A. (2018). Clinical implications of genetic diagnostics. *Nursing Clinics of North America*, 53(2), 239–255. <https://doi.org/10.1016/j.cnur.2018.02.005>
66. Rivers, D., & May, S. (2023). Integrating genomics into routine nursing practice. *Journal of Nursing Scholarship*, 55(1), 58–68. <https://doi.org/10.1111/jnu.12798>

67. Roden, D. M., & Wilke, R. A. (2007). Pharmacogenomics and drug-induced arrhythmias. *Heart Rhythm*, 4(2), 225–226. <https://doi.org/10.1016/j.hrthm.2006.12.032>
68. Ropers, K., Schalles, S., & Zang, K. D. (2017). Pharmacogenetics of psychiatric disorders. *Pharmacopsychiatry*, 50(3), 100–110. <https://doi.org/10.1055/s-0043-108939>
69. Ross, C. J. D., Visscher, H., Sistonen, J., & Carleton, B. C. (2015). Pharmacogenomics in acute care medicine. *Pharmacogenomics*, 16(3), 201–204. <https://doi.org/10.2217/pgs.14.170>
70. Sabatini, L. M., Mathews, R., & Sarangi, V. (2016). Preventing harm through pharmacogenetics. *Journal of the American Pharmacists Association*, 56(3), 302–307. <https://doi.org/10.1016/j.japh.2016.02.002>
71. Saeed, A., Al Sayyari, A., Alamri, H. S., & Alharbi, M. M. (2024). Whole-genome sequencing in medication safety. *Frontiers in Pharmacology*, 14. <https://doi.org/10.3389/fphar.2023.1333342>
72. Salari, K., Watkins, H., & Ashley, E. A. (2012). Personalized medicine: Hope or hype? *European Heart Journal*, 33(13), 1564–1570. <https://doi.org/10.1093/eurheartj/ehr476>
73. Saraç, R., & Çolak Araz, A. (2024). Nurses' role in pharmacogenomics and patient care. *Journal of Nursing Management*, 32(4), 1198–1205. <https://doi.org/10.1111/jonm.13941>
74. Schleidgen, S., Klingler, C., Bertram, T., Rogowski, W., & Marckmann, G. (2013). Defining precision medicine. *Journal of Personalized Medicine*, 3(4), 279–287. <https://doi.org/10.3390/jpm3040279>
75. Schwartz, G. G., & Patrick, J. H. (2020). Pharmacogenomics in cardiology. *Trends in Cardiovascular Medicine*, 30(7), 412–420. <https://doi.org/10.1016/j.tcm.2019.07.002>
76. Sears, K. (2012). Genomics and nursing practice: Update and future directions. *International Journal of Nursing Knowledge*, 23(2), 113–118. <https://doi.org/10.1111/j.2047-3095.2012.01217.x>
77. Sethi, R., Singh, K., & Gupta, R. (2022). Clinical pharmacogenomics in oncology. *Cancer Treatment Reviews*, 107, 102414. <https://doi.org/10.1016/j.ctrv.2022.102414>
78. Shah, R. R. (2013). Pharmacogenetics and pharmacogenomics: Past, present and future. *Drug Safety*, 36(7), 455–460. <https://doi.org/10.1007/s40264-013-0047-1>
79. Shastry, B. S. (2006). Pharmacogenetics and the concept of personalized medicine. *Pharmacogenomics Journal*, 6(1), 16–21. <https://doi.org/10.1038/sj.tpj.6500347>
80. Shebl, N. A., Ashcroft, D. M., & Hewitt, J. (2009). Medication errors: Role of pharmacogenomics. *International Journal of Pharmacy Practice*, 17(1), 31–36. <https://doi.org/10.1211/ijpp.17.01.0005>
81. Shimazawa, R., & Ikeda, M. (2020). Regulatory challenges in genetic testing. *Journal of Evidence-Based Medicine*, 13(2), 155–160. <https://doi.org/10.1111/jebm.12411>
82. Singh, A. (2021). Application of machine learning in drug response prediction. *Computers in Biology and Medicine*, 134, 104535. <https://doi.org/10.1016/j.combiomed.2021.104535>
83. Skaar, T. C., & Desta, Z. (2020). Genotype-guided therapy in clinical settings. *Clinical Pharmacology & Therapeutics*, 107(1), 110–122. <https://doi.org/10.1002/cpt.1637>

84. Slade, D., & Molster, C. (2015). Public perspectives on personalized medicine. *European Journal of Human Genetics*, 23(11), 1533–1540. <https://doi.org/10.1038/ejhg.2015.28>
85. Smith, Y., & Johnson, L. (2023). The nurse's role in interpreting genetic test results. *Journal of Clinical Nursing*, 32(5–6), 1123–1131. <https://doi.org/10.1111/jocn.16219>
86. Suhre, K., Raffler, J., & Kastenmüller, G. (2016). Metabolomics in precision medicine. *Molecular Systems Biology*, 12(7). <https://doi.org/10.15252/msb.20156242>
87. Tamburrini, C., & Minacori, R. (2019). Legal and ethical considerations in pharmacogenomics. *Journal of Law and the Biosciences*, 6(1). <https://doi.org/10.1093/jlb/lbz009>
88. Teutsch, S. M., & Bradley, L. A. (2009). Evaluation of genetic tests. *Genetics in Medicine*, 11(10), 769–773. <https://doi.org/10.1097/GIM.0b013e3181b2e314>
89. Thorn, C. F., Klein, T. E., & Altman, R. B. (2010). Pharmacogenomics and individualized medicine. *Pharmacological Reviews*, 62(3), 419–436. <https://doi.org/10.1124/pr.110.003533>
90. Trusheim, M. R., Berndt, E. R., & Douglas, F. L. (2007). Stratified medicine: A model for drug development in the era of genomics. *Health Affairs*, 26(1), 63–72. <https://doi.org/10.1377/hlthaff.26.1.63>
91. Tzeng, W.-C., Chen, S.-L., & Lin, C.-C. (2018). Nurses' knowledge of pharmacogenomics. *Journal of Nursing Research*, 26(2), 84–92. <https://doi.org/10.1097/jnr.0000000000000210>
92. Van Driest, S. L., & Wells, Q. S. (2016). Pharmacogenomics in clinical practice. *Annual Review of Pharmacology and Toxicology*, 56, 155–175. <https://doi.org/10.1146/annurev-pharmtox-010715-103036>
93. Vassy, J. L., & Christensen, K. D. (2017). Secondary genomic findings. *New England Journal of Medicine*, 376(1), 61–70. <https://doi.org/10.1056/NEJMs1508326>
94. Verma, R., & Gupta, V. (2020). Pharmacogenomics in psychiatry. *Indian Journal of Psychological Medicine*, 42(6), 506–513. <https://doi.org/10.1177/0253717620952378>
95. Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011). Genomics and drug response. *New England Journal of Medicine*, 364(12), 1144–1153. <https://doi.org/10.1056/NEJMra1010600>
96. Whirl-Carrillo, M., et al. (2012). Pharmacogenomics knowledge base. *Clinical Pharmacology & Therapeutics*, 92(4), 414–417. <https://doi.org/10.1038/clpt.2012.96>
97. Wright, C. F., et al. (2019). Challenges in clinical genome testing. *Nature Reviews Genetics*, 20(3), 153–168. <https://doi.org/10.1038/s41576-018-0083-7>
98. Wu, A. H. (2011). Pharmacogenomic testing: Current and future applications. *Therapeutic Drug Monitoring*, 33(4), 347–353. <https://doi.org/10.1097/FTD.0b013e318226079c>
99. Yip, S. (2013). Genomics-driven oncology. *Nature Reviews Clinical Oncology*, 10, 341–352. <https://doi.org/10.1038/nrclinonc.2013.67>
100. Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 polymorphisms in drug metabolism. *Pharmacology & Therapeutics*, 138(1), 103–141. <https://doi.org/10.1016/j.pharmthera.2012.12.007>
101. Zhang, F., Finkelstein, J., Cohen, J., & Chen, Y. (2019). Integrating pharmacogenomic data in EHR systems. *Journal of Biomedical Informatics*, 94, 103182. <https://doi.org/10.1016/j.jbi.2019.103182>

102. Zhang, L., Dolan, M. E., & Zhang, W. (2010). The emerging role of pharmacogenomics in oncology. *Cancer Treatment and Research*, 145, 113–129. [https://doi.org/10.1007/978-1-4419-6753-5\\_9](https://doi.org/10.1007/978-1-4419-6753-5_9)
103. Zhou, S. F., Liu, J. P., & Chowbay, B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. *Drug Metabolism Reviews*, 41(2), 89–295. <https://doi.org/10.1080/03602530902843483>
104. Zineh, I. (2015). Personalized medicine: Reality or myth? *Clinical Pharmacology & Therapeutics*, 97(3), 245–247. <https://doi.org/10.1002/cpt.76>
105. Zubair, M. (2024). Development of education index, governance index, and health index. *Journal of Population and Social Studies*, 32, 1–16. <https://doi.org/10.25133/JPSSv32n1.001>
106. Vaivada, T., Liu, L., Pal Bhutta, Z. A., Bhutta, Z. A., & Black, R. E. (2017). Pharmacogenomics and global child health. *PLOS Medicine*, 14(4), e1002292. <https://doi.org/10.1371/journal.pmed.1002292>
107. Esmaeili, R., & Sharifi, S. (2018). Drug–gene interactions and therapy individualization. *Iranian Journal of Basic Medical Sciences*, 21(8), 770–778. <https://doi.org/10.22038/ijbms.2018.26756.6539>
108. Yang, L., Kong, X., & Wang, Z. (2014). Emerging trends in personalized medicine. *Journal of Genetics and Genomics*, 41(3), 117–126. <https://doi.org/10.1016/j.jgg.2014.01.002>
109. Van Rooij, T., & Verma, S. (2022). Clinical genomics: Barriers and breakthroughs. *Nature Biotechnology*, 40(6), 857–866. <https://doi.org/10.1038/s41587-022-01215-3>
110. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25(1), 44–56. <https://doi.org/10.1038/s41591-018-0300-7>
111. Khoury, M. J., Feero, W. G., & Chambers, D. A. (2016). Progress and challenges in genomic medicine implementation. *Health Affairs*, 35(5), 807–813. <https://doi.org/10.1377/hlthaff.2015.1418>
112. Mills, R., & Haga, S. B. (2014). Clinical delivery of pharmacogenetic testing. *Pharmacogenomics and Personalized Medicine*, 7, 285–294. <https://doi.org/10.2147/PGPM.S48800>
113. McCarthy, J. J., & McLeod, H. L. (2013). Pharmacogenetics in clinical practice. *Human Genetics*, 132(2), 175–184. <https://doi.org/10.1007/s00439-012-1221-z>
114. Palmer, G. C., Penrod, N. M., & Marrouche, N. F. (2016). Genomic medicine in cardiology. *Journal of the American Heart Association*, 5(7). <https://doi.org/10.1161/JAHA.116.003941>
115. Lee, C. H., & Lee, J. H. (2018). Pharmacogenomics in psychiatric care. *Nature Human Behaviour*, 2(7), 422–430. <https://doi.org/10.1038/s41562-018-0370-8>
116. Marquart, J., Chen, E. Y., & Prasad, V. (2018). Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. *JAMA Oncology*, 4(8), 1093–1098. <https://doi.org/10.1001/jamaoncol.2018.1660>
117. Yadav, R., & Shastri, S. (2020). Pharmacogenomics and cardiovascular drugs. *Current Cardiology Reports*, 22(11), 147. <https://doi.org/10.1007/s11886-020-01390-4>

118. Mirnezami, R., Nicholson, J., & Darzi, A. (2012). Preparing for precision medicine. *New England Journal of Medicine*, 366(6), 489–491. <https://doi.org/10.1056/NEJMp1114866>
119. Jain, K. K. (2015). Personalized medicine in neurological diseases. *Drug Discovery Today*, 20(3), 319–324. <https://doi.org/10.1016/j.drudis.2014.10.005>
120. Li, Q., & Zhao, R. (2021). Advances in genomic nursing. *Journal of Advanced Nursing*, 77(6), 2654–2666. <https://doi.org/10.1111/jan.14840>
121. Fordin, S., & Choi, E. (2020). Big data in pharmacogenomics. *Annual Review of Biomedical Data Science*, 3, 1–25. <https://doi.org/10.1146/annurev-biodatasci-020520-093815>
122. Caswell-Johnson, E., & Hamilton, R. (2021). Ethical implications of genomic nursing practice. *Nursing Ethics*, 28(7–8), 1201–1213. <https://doi.org/10.1177/09697330211003205>
123. Mendes, Á., & Ladeira, I. (2022). Artificial intelligence for pharmacogenomics research. *Computational and Structural Biotechnology Journal*, 20, 1233–1247. <https://doi.org/10.1016/j.csbj.2022.02.006>
124. Donnelly, M., & Parsons, K. (2023). Digital health tools in personalized medicine. *Nature Reviews Digital Health*, 2(3), 150–162. <https://doi.org/10.1038/s44222-023-00036-9>
125. Fan, J., Zeng, L., & Cai, W. (2020). Molecular diagnostics in precision oncology. *Cancer Letters*, 470, 142–150. <https://doi.org/10.1016/j.canlet.2019.11.015>
126. Krishnan, V., & Bose, A. (2021). Nurses' preparedness for genomic medicine. *Nurse Education Today*, 103, 104963. <https://doi.org/10.1016/j.nedt.2021.104963>
127. Rao, G., & Andrews, M. (2019). Tele-genomics and its application in patient care. *Telemedicine and e-Health*, 25(9), 835–844. <https://doi.org/10.1089/tmj.2018.0194>
128. Anderson, N., & Johnson, M. (2018). Wearable technologies for personalized health monitoring. *Sensors*, 18(7), 2412. <https://doi.org/10.3390/s18072412>
129. Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: From science to value. *Health Affairs*, 37(5), 694–701. <https://doi.org/10.1377/hlthaff.2017.1624>
130. Cavallari, L. H., & Johnson, J. A. (2022). Pharmacogenomics implementation: The intersection of science and practice. *Annual Review of Pharmacology and Toxicology*, 62, 1–21. <https://doi.org/10.1146/annurev-pharmtox-051821-092507>
131. Lee, Y. J., & Lee, S. H. (2021). Personalized nutrition and genomics. *Annual Review of Nutrition*, 41, 1–22. <https://doi.org/10.1146/annurev-nutr-082120-045437>
132. Herkert, J. C., & Abbott, K. M. (2017). Teaching genomics in nursing programs. *Nurse Educator*, 42(5), 245–250. <https://doi.org/10.1097/NNE.0000000000000372>
133. Denny, J. C., Collins, F. S., & Kirschner, M. (2022). Precision medicine: Data, diagnostics, and delivery. *Cell*, 185(8), 1390–1409. <https://doi.org/10.1016/j.cell.2022.03.009>
134. Sadée, W., & Dai, Z. (2005). Pharmacogenetics/genomics and personalized medicine. *Human Molecular Genetics*, 14(R2), R207–R214. <https://doi.org/10.1093/hmg/ddi266>
135. Giraud, C., & Ropars, V. (2023). Personalized oncology and health equity. *Cancer Epidemiology*, 81, 102334. <https://doi.org/10.1016/j.canep.2023.102334>



136. Khoury, M. J., Bowen, S., & Clyne, M. (2021). Genomics translation and implementation. *Annual Review of Public Health, 42*, 175–197. <https://doi.org/10.1146/annurev-publhealth-090419-102409>
137. Comis, R. L., Miller, J. D., Aldigé, C. R., Krebs, L., & Stoval, E. (2003). Public attitudes on clinical trials. *Journal of the American Medical Association, 289*(19), 2542–2550. <https://doi.org/10.1001/jama.289.19.2542>
138. Burke, W., Matheny Antommara, A. H., Bennett, R., Botkin, J., Clayton, E. W., Henderson, G. E., Holm, I. A., Jarvik, G. P., Khanna, A., & Knoppers, B. M. (2013). Recommendations for returning genomic results. *Genetics in Medicine, 15*(7), 563–567. <https://doi.org/10.1038/gim.2013.73>
139. Wakefield, C. E., & Meiser, B. (2010). Family communication of genetic information. *European Journal of Human Genetics, 18*, 791–796. <https://doi.org/10.1038/ejhg.2010.27>
140. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. *Nature, 526*(7573), 343–350. <https://doi.org/10.1038/nature15817>
141. Pasternak, A. L., & Alagoz, O. (2018). Cost-effectiveness of precision medicine. *PharmacoEconomics, 36*(2), 175–186. <https://doi.org/10.1007/s40273-017-0580-8>
142. Zeggini, E., & Gloyn, A. L. (2019). Translating genetics into practice. *Nature Reviews Genetics, 20*(7), 381–392. <https://doi.org/10.1038/s41576-019-0120-0>